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binary restenosis
rate(%)
O( 0%)
5(12%)
3
reference MLD stenosis
diameter (mm) (mm) (%)
pre procedure 294 ± 0.37 094 ± 0.28 68.7 ± 9.9
pre-dilatation 2.91 ± 0.36 159 ± 032 45.9 ± 13.5
post stenting 2.89 ± 0.39 269 ± 0.22 59 ± 10.8
next day In ~ 36) 2.88 ± 032 2.64 ± 0.21 8.0± 8.0
1mo FlU (n = 35) 291 ± 0.35 2.57 ± 023 11.2± 8.7
3moF/U(n = 41) 2.84 ± 0.32 2.02 ± 0.52 28.9 ± 17.3
6 mo FlU (n = 15) 2.84 ± 0.32 1.82 ± 0.56 36.6 ± 18.2
Complications
Repeat angioplasty was required in 4 of 8 patients with restenosis. Thus,
the Cordis stent implantation can be achieved with a high degree of technical
and clinical success because of its flexible design and good visibility. Further-
more, its very low complication rates are encouraging. Restenosis rate at 3
months follow-up period is acceptably low.
acutelsubacute occlusion: 0 OInon Q-MI: 1 12%) CABG: 0
death: 0 groin hematoma: 2 (4%) blood transfusions: 3 (5%)
Angiographic findings lesion length: g.O ± 5.4 mm
In order to assess the safety and efficacy of Wiktor Stent (WS) implantation,
data from the French WS registry were reviewed. Between February 1991
and April 1994, 245 stent placements were attempted in 225 patients for
acute or threatening vessel closure after PTCA in 119 (52.9%), nonocclusive
dissection in 11 (4.9%), suboptimal dilatation in 30 (13.3%), restenosis in 55
(24.5%) and de novo lesions in 10 (4.4%). Implanted site was LAD in 34.7%,
RCA in 40.9%, left Circumflex in 16%, left main in 1.3% and saphenous graft
in 7.1 %. Stent placement was successful in 93.8% of patients (pts). Failure
was due to peripheral stent migration in 2 pts, inability to cross the lesion
in 8, non-target placement in one and acute occlusion in 3 others. Ten pts
(4.4%) underwent emergent CABG. Death occurred in 5 pts (2.2%) and was
due to cardiac complications in 3 and intracerebral hemorrhage in 2. Sub-
acute thrombosis occurred in 9 pts (4%). Clinical success rate (procedural
success without in hospital death, CABG or MI) was 86.2%. Vascular com-
plications occurred in 4 pts (1.8%). To date. coronary angiography has been
performed in 120/172 (69.8%) eligible pts and showed restenosis (>50%
stenosis) in 26.7%. Factors associated with restenosis were male gender,
current smoking and site of implantation.
Conclusion: WS implantation is very efficacious in reversing critical situa-
tions after angioplasty while carrying an acceptable risk.
Clinical Experience with Medtronic Wiktor Stent
Implantation: A Report from the French
Multicentric Registry
Elie K. Karouny, Khalife Khalife, Jean-Pierre Monassier, Bernard Lancelin,
Gilles Grollier, Didier Carrie, Bernard Assoun, Michel Jean, Jacques Pue!.
Cardiologie Purpan, Toulouse, France
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care. The system can also be accessed remotely via modem to permit its
use as a revascularization "consultant."
Conclusion: This program automatically and objectively determines
ACC/AHA, RAND and RAS revascularization appropriateness ratings. It is a
useful tool for evaluating appropriateness of PTCA or CABG in individual pa-
tients as well as for analyzing patterns of care.
The results of Balloon expandable Micro Stent'" (Applied Vascular Engineer-
ing Canada, Inc) were analyzed. This stent is unique in that it comes pre-
mounted on a balloon in non articulated multiples of 4 mm units. The stent is
available in 4, 8 and 12 mm lengths. The short stent unit length allows it to be
used in short lesions, tortuous anatomy, and for complex situations such as
stent delivery through a deployed stent. 16 lesions in 15 patients (pts) were
treated with Micro stent. A one unit (4 mm) stent was used in 3 lesions, a 2
unit (8 mm) stent in 3 lesions and a 3 unit stent (12 mm) stent in 8 lesions re-
spectively. Indication for stent implantation was elective in 15 lesions and for
acute closure after balloon angioplasty in 1 lesion. Vessel distribution was 8
LCX (50%). 5 RCA (31 %) and 3 LAD (19%). In 8 lesions (50%) other types of
stents (Palmaz-Schatz, Gianturco-Roubin orWiktor stent} were deployed. The
reason for the selection of Micro Stent was failed stent delivery using other
type of stents in 9 (56%). tortuous vessel in 4 lesions and for 3 short lesions.
Stent deployment in 8 (50%) lesions were performed through a previously
deployed stent. There was 1 delivery failure due to a failure to pre dilate the
lesion. Intracoronary ultrasound was performed to confirm the optimal stent
expansion and position. Stent migration was noted in 3 lesions. When stent
expansion was optimized, pts received no anticoagulation and either aspirin
325 mglday or Ticlopidine 500 mglday for 1 month with aspirin 325 mg for
5 days. 13 patients (87%) were treated without anticoagulation after stent
deployment. Ouantitative angiographic (AG) measurements is shown in the
table below:
Preliminary Experience of Coronary Stenting with
the Micro Stent™
Antonio Colombo, Luigi Maiello, Shigeru Nakamura, Patrick Hall,
Simonetta Blengino, Leo Finci, Giovanni Martini. Columbus Hospital, Milan, Italy
There was no stent thrombosis at 1 month follow up.
Conclusions. (1) The Micro stent showed high trackability despite complex
anatomy or delivery failure with other types of stents. (2) Stent delivery to dis-
tal lesions through a deployed stent was successful in all cases. (3) When
optimal Micro stent expansion is achieved. antiplatelet therapy (without anti-
coagulation) is effective in preventing stent thrombosis despite use in small
vessels.
Naoya Hamasaki, Hideyuki Nosaka, Masakiyo Nobuyoshl. Kokura Memorial
Hospital, f(jtakyushu, Japan
To assess the safety and efficacy of the Cordis stent, implantation was at-
tempted in 63 consecutive patients and 64 lesions from Jan. to Aug. 1994
(mean age: 63 years, % male: 79%, % previous MI: 62%, % multi vessel
disease: 47%). The balloon expandable Cordis stent was made up of a sin-
gle strand, very flexible, radiopaque continuous tantalum wire, and was 3.0
or 3.5 mm in diameter and 18 mm in length. The Cordis stent was implanted
electively in 44 lesions (69%), thirty-four of the 64 (58%) were restenotic le-
sions. Locations of the stented artery were LMT in 1, LAD in 28, LCX in 10
and RCA in 25 lesions (single stealing: 51. multiple stenting: 13,3.0 mm
stent: 39, 3.5 mm stent: 25). Unfavorable angiographic morphology (eccen-
tricity, dissection. calcification. ulceration or bend > 45') was noted in 43
lesions (67%). Delivery success was achieved in 57 lesions (90%). Rescue
stenting with this stent after the placement of a different stent had failed
was successful in 3 lesions. Complications and angiographic findings are as
follows.
AntOniO Colombo, Shigeru Nakamura, Patrick Hall, Luigi Maiello, Leo Finei,
Giovanni Martini. Columbus Hospital, Milan, Italy
The Wiktor coronary stent has been implanted in 82 lesions in 68 patients.
The indication for stent implantation was 49 elective (57%), 10 threatened
closure (12%), 9 SUboptimal PTCA (11 %), 7 chronic total occlusion (9%), 4
restenosis (5%), and 3 acute occlusion (4%). Vessel distribution was 39 RCA
(48%), 31 LAD (37%) and 12 LCX (15%). Successful stent implantation was
achieved in 77 lesions (94%). Average Wiktor stent per lesion was 1.4 ±
0.8 (range 1 to 4). More than one stent was used in 53 patients (69%). Le-
sion length was 14.8 ± 9.7 mm. Final balloon/vessel ratio was 1.03 ± 0.15.
Maximum inflation pressure was 16 ± 3 atmospheres. There were 5 lesions
that required an additional Palmaz-Schatz stent inside the Wiktor to reinforce
the lumen support. Mild stent structural deformity (expanded strut gap) was
seen in 8 lesions. There were 5 stents with severe stent deformity due to
shrinkage (n = 3) or uncoiling (n = 2). 59 patients (93%) with 72 lesions
(88%) of were treated with only antiplatelet therapy after stent implantation
with intravascular ultrasound guidance. There were 2 CABG due to stent se-
vere stent deformity. One death was due to femoral artery occlusion with
multiple organ failure. To date, 35 of an eligible 59 lesions (59%) received
4-6 months angiographic follow up (F/U)
A Prospective Study of Wiktor Coronary Stent
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Initial Experience of Cordis Stent Implantation1967-171
There was one stent thrombosis that occurred 8 days after the stent proce-
dure and 5 days after antiplatelet therapy was inadvertently stopped. Wiktor
stent restenosis by ::::50% diameter stenosis was present in 8 patients (23%).
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Conclusions. (1) Short term results and restenosis rate after Wiktor stent
implantation without subsequent anticoagultion is encouraging. (2) Mild or
significant structural deformity was found in 13 (16%) of stents.
Parameter Stainless Steel Nitinol Nitinol ANOVA
4 day 4day 14 day p-value
n 8 8 6
Carotid flow (ml/min) 1.5 ± 2.8 24.0 ± 2.0 255 ± 19 <0.000001
Thrombus grade 111= 2. IV = 6 1=8 1=6 <0.0001
Thrombus weight (mg) 200 ± 5.9 25 ± 06 2.7 ± 03 <0.000001
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Molecular Aspects of Arterial Injury
Thrombin Generation and Systemic Inflammatory
Response After Coronary Stent Implantation
Ilka Ott. Franz-Josef Neumann, Meinrad Gawaz, Andreas May, Albert Schbmig.
Medizinische Klinik der Technischen Universitat Miinchen
Previously, using immunocytochemistry for the proliferating cell nuclear anti-
gen, we detected low levels of replication (~1%) in 100 restenotic coronary
atherectomy specimens. Histone H3 mRNA increases 3D-50-fold as cells
pass through S phase of the cell cycle and can be used as an independent
marker of cell replication. Therefore, using in situ hybridization for histone
H3 mRNA we examined the proliferative profile of: i) coronary atherectomy
specimens (n = 12) obtained within the first 60 days after a previous in-
terventional procedure, and ii} primary (n = 13) and restenotic (n = 10) pe-
ripheral atherectomy specimens because of their larger tissue sample size.
For these respective tissue groups, the number of specimens that had any
cells expressing histone mRNA on a slide were 2/12, 5/13 and 7/10. The to-
tal number of cells per slide expressing histone H3 mRNA ranged from 0 to
23.0 to 82 and 0 to 118 for these 3 groups of specimens. Typical coronary
and peripheral atherectomy specimens contain 4,500 and 10,200 cells per
slide, respectively. Therefore, the highest replication profiles (0.5%, 1.2%)
were seen in restenotic coronary and peripheral artery specimens obtained
1 and 2 days post-atherectomy, respectively. Smooth muscle and endothe-
lial cells expressed histone H3 mRNA. Conclusions: These results suggest
that: 1) replication is a modest event in human atherosclerosis and resteno-
sis; 2) replication may be more prevalent in peripheral compared to coronary
atherectomy specimens; and 3) anecdotally, an important time window for
proliferation may be in the days immediately post-intervention.
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Conclusion: After coronary stent implantation a systemic inflammatory re-
action occurs. Its extend may have a causative relationship to the thrombin
generation during stent implantation.
In patients with severe coronary artery disease a systemic inflammatory re-
action (SIRS) occurs that contributes to thrombotic complications. To evalu-
ate the systemic inflammatory response in patients with coronary stent im-
plantation, serial venous blood samples were taken in 101 patients before
and after stent implantation. Humoral and cellular inflammatory markers as
well as the prothrombin-fragments Fl + 2 were analysed. An initial elevated
thrombin generation was followed by an increased integrin surface expres-
sion (CDll b, FACScan) on monocytes (Mo) and granulocytes (PMN) (plateau
after 2 days) and by an increase in plasma fibrinogen (fbg) and C-reactive pro-
tein (CRP) (plateau after 5 days).
The initial Fl + 2 peak correlated significantly with fbg and CRP at day 5
(r = 0.07 and 0.31, p = 0.0001) and with CDll b surface expression on Mo
at day 2 (r = 0.02, P < 0.05) and on PMN by trend (p < 0.1).
Evaluation of Proliferation In Human Atherectomy
Specimens Using In Situ Hybridization for
Histone H3
Edward R. O·Brien. Simcha Urieli-Shoval. Michael R. Garvin. Earl P. Bendit!.
Douglas K. Stewart. Tomoaki Hinohara, John B. Simpson. Stephen M. Schwartz.
University of Washington, Seattle, WA: Sequoia Hospital, Redwood City, CA
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Reduced Thrombogenlcity of Nltinol vs Stainless
Steel Slotted-Tube Stents In Rabbit Carotid
Arteries
Long Term Results of Balloon Expandable
Slotted·Tube Nltlnol Stents In Canine Coronary
Arteries
number
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balloon to artery ratio
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percent recoil
Histologic examination of stented arterial segments showed that although
the depth of strut penetration was similar in all 4 day rabbits. the group with
stainless steel stents consistently had evidence of diffuse medial necrosis
and thinning (8/8 vs 118; P = 0.0004). Conclusions: Nitinol stents developed
significantly less thrombus in comparison to stainless steel stents of sim-
ilar design as measured by thrombus weight. thrombus grade and degree
of blood flow reduction at 4 days in the rabbit carotid artery model. For niti-
nol stents there was no worsening of these thrombotic parameters at 14
days, compared to 4 days. More severe vascular injury may contribute to
the thrombogenicity of stainless steel stents.
At follow-up, all vessels and 9 of 9 stented sidebranches were patent. The
mean percent stenosis at 3 to 6 months was -1.6 ± 5.2 and the late loss
was 0.2 ± 0.3 mm. All struts were covered with neointima at 2 weeks. At 6
months the maximal neointimal thickness was 260 ± 50 f.l.m and was located
adjacent to the struts. No thrombi and only occasional areas of granulation
tissue with rare inflammatory cells were seen. Conclusions: A slotted tube
nitinol stent has delivery performance characteristics and recoil similar to
stainless steel slotted-tube stents. Nitinol stents endothelialize rapidly and
intimal proliferation is insufficient to create a stenosis in this animal model.
These data suggest that a slotted-tube, balloon expandable nitinol stent is
sufficiently reliable and biocompatible to warrant clinical trials.
Kenneth Mahrer, Bruce Samuels. Hua' Luo. Michael C. Fishbein, James
S. Forrester, Frank Litvack, Neal Eigler. Cedars-Sinai Medical Center. Los Angeles. CA
This study evaluated delivery performance, quantitative angiographic param-
eters, intravascular ultrasound appearance. long term patency and vascular
histology of radio-opaque, slotted-tube nickel titanium (nitinoll stents perma-
nently implanted in canine coronary arteries. Dogs were treated with aspirin
for 1 month. Follow-up angiography and histology were performed at 0.5,
1, 3, and 6 months (number of vessels = 2,4, 6, and 26, respectively). Re-
sults: Thirty-eight of 39 (97%) stents were successfully implanted in the mid
LAD and LCX of 20 dogs. One stent, which was undersized, was success-
fully removed by thermal recovery. Tandem stents were placed in 2 dogs
without difficulty. Intravascular ultrasound of 6 stents showed symmetrical
expansion with good wall contact. Acute angiographic parameters:
Sushil Sheth. Vishva Dev. Michael C. Fishbein. James S. Forrester. Frank Litvack.
Neil L. Eigler. Cedars-Sinai Medical Center. Los Angeles, CA
The thrombogenicity of slotted-tube stents made of nitinol or stainless steel
(Palmaz Schatz) was assessed in a rabbit carotid artery model. Fourteen niti-
nol and 8 stainless steel stents (7 mm long single segment stents) were de-
ployed in a carotid artery of 22 NZW rabbits with a 3.0 mm balloon inflated
twice at 6 atm for 1 min. No antiplatelet or antithrombotic drugs were given.
Eight rabbits with nitinol and 8 with stainless steel stents were euthanized
after 4 days. The remaining 6 rabbits with nitinol stents were euthanized after
14 days. At sacrifice, both carotids (stented and control) were exposed and
resting blood flow measured. The amount of thrombus on each stent was
assessed by a semi-quantitative grading scale (I: no lumen encroachment; II:
lumen encroachment; III: subocclusive thrombus; and IV: occlusive throm-
bus) and by the weight of the dry thrombus. Results: All nitinol were patent
at 4 and 14 days whereas 6 out of 8 (75%) stainless steel stents had total
thrombotic occlusion at 4 days (p < 0.0001).
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